🍽️ celecoxib,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Osteoarthritis: Celecoxib is commonly prescribed for the management of osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage in the joints. It helps reduce pain, stiffness, and swelling associated with this condition, thereby improving mobility and quality of life.

  2. Rheumatoid Arthritis: Celecoxib is also used in the treatment of rheumatoid arthritis, an autoimmune disease that causes inflammation of the joints. It helps alleviate symptoms such as joint pain, swelling, and stiffness, and may slow down the progression of the disease.

  3. Ankylosing Spondylitis: Celecoxib is indicated for the symptomatic treatment of ankylosing spondylitis, a chronic inflammatory arthritis affecting the spine and large joints. It helps reduce pain and stiffness associated with this condition, improving flexibility and function.

  4. Acute Pain: Celecoxib may be prescribed for the short-term relief of acute pain, such as that caused by dental procedures, surgery, or injury. It provides analgesic effects by inhibiting the production of inflammatory mediators in the body.

  5. Menstrual Cramps: Celecoxib can be used to alleviate menstrual cramps (dysmenorrhea) by reducing prostaglandin levels in the uterus, which are responsible for causing uterine contractions and pain during menstruation.

  6. Chronic Pain Syndromes: In some cases, celecoxib may be used off-label for the management of chronic pain syndromes such as fibromyalgia or chronic low back pain, particularly when other treatment options have been ineffective or poorly tolerated.

  7. Colon Polyps: Celecoxib is approved for the prevention of colorectal polyps in patients with familial adenomatous polyposis (FAP), a rare inherited disorder characterized by the presence of multiple polyps in the colon and rectum. It helps reduce the number and size of polyps, potentially lowering the risk of colorectal cancer.

  8. Cardiovascular Risk: Celecoxib, like other NSAIDs, is associated with an increased risk of cardiovascular events such as heart attack and stroke, especially when used at high doses or for prolonged periods. It is generally recommended to use the lowest effective dose for the shortest duration necessary, particularly in patients with pre-existing cardiovascular risk factors.

  9. Gastrointestinal Effects: Celecoxib is associated with a lower risk of gastrointestinal ulcers and bleeding compared to traditional NSAIDs like ibuprofen or naproxen. However, it can still cause stomach upset, indigestion, and in rare cases, serious gastrointestinal complications such as perforation or bleeding.

  10. Kidney Function: Prolonged use of celecoxib may impair kidney function and increase the risk of kidney damage or failure, particularly in individuals with pre-existing kidney disease or dehydration. It is important to stay well-hydrated and monitor kidney function regularly during treatment.

  11. Allergic Reactions: Some individuals may experience allergic reactions to celecoxib, characterized by symptoms such as rash, itching, swelling of the face or throat, difficulty breathing, or severe skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis. If any of these symptoms occur, medical attention should be sought immediately.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of celecoxib,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by celecoxib,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Roseburia genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Segatella genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bacteroides ovatus species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Coprococcus comes species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Blautia obeum species Decreases 📓 Source Study
Bacteroides uniformis species Increases 📓 Source Study Infectious bacteria
Bacteroides uniformis ATCC 8492 strain Increases 👶 Source Study
Bacteroides uniformis CL03T00C23 strain Increases 👶 Source Study
Bacteroides uniformis CL03T12C37 strain Increases 👶 Source Study
Bacteroides uniformis dnLKV2 strain Increases 👶 Source Study
Bacteroides uniformis str. 3978 T3 i strain Increases 👶 Source Study
Bacteroides uniformis str. 3978 T3 ii strain Increases 👶 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of celecoxib,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 2.4 0.1 23
Age-Related Macular Degeneration and Glaucoma 0.5 0.4 0.25
Allergic Rhinitis (Hay Fever) 0.8 0.8
Allergies 0.6 0.7 -0.17
Allergy to milk products 0.3 0.4 -0.33
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 0.9 1.9 -1.11
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.1 1.1
Ankylosing spondylitis 1.6 0.3 4.33
Anorexia Nervosa 0.4 1 -1.5
Antiphospholipid syndrome (APS) 1.6 1.6
Asthma 0.8 -0.8
Atherosclerosis 2.5 -2.5
Atrial fibrillation 1 1.5 -0.5
Autism 3.3 3.6 -0.09
Barrett esophagus cancer 0 0
Bipolar Disorder 0.8 0.6 0.33
Brain Trauma 0.8 -0.8
Carcinoma 1.3 1.3 0
Celiac Disease 1.6 1.3 0.23
Cerebral Palsy 0 0.8 0
Chronic Fatigue Syndrome 1.5 4 -1.67
Chronic Kidney Disease 0.8 0.8 0
Chronic Lyme 0.8 -0.8
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.6 -5
Chronic Urticaria (Hives) 0 1.3 0
Coagulation / Micro clot triggering bacteria 0.5 0.5 0
Colorectal Cancer 2.4 0.1 23
Constipation 1 0.5 1
Coronary artery disease 0.1 0.1 0
COVID-19 3.7 6.3 -0.7
Crohn's Disease 2.4 2.7 -0.13
cystic fibrosis 0.8 -0.8
deep vein thrombosis 0.5 -0.5
Depression 3.9 3.1 0.26
Dermatomyositis 0 0
Eczema 0.7 -0.7
Endometriosis 0.9 0.5 0.8
Epilepsy 1 1.7 -0.7
Fibromyalgia 1.8 1.2 0.5
Functional constipation / chronic idiopathic constipation 3.9 2.2 0.77
gallstone disease (gsd) 0.4 0.5 -0.25
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.3 0.1 12
Generalized anxiety disorder 0 0.4 0
Glioblastoma 0 0
Gout 0.1 -0.1
Graves' disease 0.8 0.5 0.6
Halitosis 0.3 0 0
Hashimoto's thyroiditis 0.8 0.3 1.67
Hidradenitis Suppurativa 0 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 1.3 0.2 5.5
hypercholesterolemia (High Cholesterol) 0.5 0.5
hyperglycemia 0.8 -0.8
hypersomnia 0 0
hypertension (High Blood Pressure 0.8 2 -1.5
Hypothyroidism 0.1 -0.1
Hypoxia 0.8 0.8
IgA nephropathy (IgAN) 2.2 -2.2
Inflammatory Bowel Disease 1 4.4 -3.4
Insomnia 0.4 0.8 -1
Intelligence 0.1 0.7 -6
Intracranial aneurysms 0.8 0.8
Irritable Bowel Syndrome 1.4 2.8 -1
Liver Cirrhosis 1.9 0.9 1.11
Long COVID 2.8 2.6 0.08
Low bone mineral density 0.6 -0.6
Lung Cancer 0 0
ME/CFS with IBS 0 0.5 0
ME/CFS without IBS 0.2 1.2 -5
Menopause 0.8 0.8
Metabolic Syndrome 2.4 3.2 -0.33
Mood Disorders 4 3.1 0.29
multiple chemical sensitivity [MCS] 0.1 0 0
Multiple Sclerosis 0.6 3.7 -5.17
Multiple system atrophy (MSA) 0 0
Neuropathy (all types) 0.1 0.1
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.8 1.2 -0.5
Obesity 2.4 1.7 0.41
obsessive-compulsive disorder 3 1.8 0.67
Osteoarthritis 0.4 0.4
Osteoporosis 0.3 0.4 -0.33
pancreatic cancer 0.5 0.5
Parkinson's Disease 0.5 2.3 -3.6
Polycystic ovary syndrome 1.5 1 0.5
Postural orthostatic tachycardia syndrome 0.1 -0.1
Premenstrual dysphoric disorder 0 0.4 0
primary biliary cholangitis 0 0
Psoriasis 0.6 2.9 -3.83
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.1 2 0.05
Rosacea 0.5 -0.5
Schizophrenia 1.4 0.6 1.33
scoliosis 0.1 0.1
Sjögren syndrome 1.7 1 0.7
Sleep Apnea 0.1 0.9 -8
Small Intestinal Bacterial Overgrowth (SIBO) 0 0
Stress / posttraumatic stress disorder 1.3 0.9 0.44
Systemic Lupus Erythematosus 1.9 1 0.9
Tic Disorder 1.2 0.7 0.71
Tourette syndrome 0.3 -0.3
Type 1 Diabetes 2.5 1.2 1.08
Type 2 Diabetes 3.1 3.3 -0.06
Ulcerative colitis 0.6 4.1 -5.83
Unhealthy Ageing 1.7 1.3 0.31

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.